Bouza, E., Valerio, M., Soriano, A., Morata, L., Carus, E. G.,
Rodriguez-Gonzalez, C., Hidalgo-Tenorio, M. C., Plata, A., Munoz, P., Vena,
A., and Group, D. S.: Dalbavancin in the treatment of different
gram-positive infections: a real-life experience, Int. J. Antimicrob. Agents,
51, 571–577, https://doi.org/10.1016/j.ijantimicag.2017.11.008, 2018.
Buchholz, H. W., Elson, R. A., Engelbrecht, E., Lodenkamper, H., Rottger,
J., and Siegel, A.: Management of deep infection of total hip replacement, J.
Bone Joint Surg. Br., 63-B, 342–353, https://doi.org/10.1302/0301-620X.63B3.7021561, 1981.
Candiani, G., Abbondi, M., Borgonovi, M., Romano, G., and Parenti, F.:
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic
glycopeptide antibiotic, J. Antimicrob. Chemother., 44, 179–192, https://doi.org/10.1093/jac/44.2.179, 1999.
Dobson, P. F. and Reed, M. R.: Prevention of infection in primary THA and
TKA, EFORT Open Rev., 5, 604–613, https://doi.org/10.1302/2058-5241.5.200004, 2020.
Dunne, M. W., Puttagunta, S., Sprenger, C. R., Rubino, C., Van Wart, S., and
Baldassarre, J.: Extended-duration dosing and distribution of dalbavancin
into bone and articular tissue, Antimicrob. Agents Chemother., 59, 1849–1855, https://doi.org/10.1128/AAC.04550-14, 2015.
Gales, A. C., Sader, H. S., and Jones, R. N.: Antimicrobial activity of
dalbavancin tested against Gram-positive clinical isolates from Latin
American medical centres, Clin. Microbiol. Infect., 11, 95–100, https://doi.org/10.1111/j.1469-0691.2004.01051.x, 2005.
Gardete, S. and Tomasz, A.: Mechanisms of vancomycin resistance in
Staphylococcus aureus, J. Clin. Invest., 124, 2836–2840, https://doi.org/10.1172/JCI68834,
2014.
Goldstein, B. P., Draghi, D. C., Sheehan, D. J., Hogan, P., and Sahm, D. F.:
Bactericidal activity and resistance development profiling of dalbavancin,
Antimicrob. Agents Chemother., 51, 1150–1154, https://doi.org/10.1128/AAC.00620-06, 2007.
Gustilo, R. B. and Anderson, J. T.: Prevention of infection in the treatment
of one thousand and twenty-five open fractures of long bones: retrospective
and prospective analyses, J. Bone Joint Surg. Am., 58, 453–458, 1976.
Hake, M. E., Young, H., Hak, D. J., Stahel, P. F., Hammerberg, E. M., and
Mauffrey, C.: Local antibiotic therapy strategies in orthopaedic trauma:
Practical tips and tricks and review of the literature, Injury, 46,
1447–1456, https://doi.org/10.1016/j.injury.2015.05.008, 2015.
Jones, R. N., Biedenbach, D. J., Johnson, D. M., and Pfaller, M. A.: In
vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent, J.
Chemother., 13, 244–254, https://doi.org/10.1179/joc.2001.13.3.244, 2001.
Jones, R. N., Fritsche, T. R., Sader, H. S., and Goldstein, B. P.:
Antimicrobial spectrum and potency of dalbavancin tested against clinical
isolates from Europe and North America (2003): initial results from an
international surveillance protocol, J. Chemother., 17, 593–600, https://doi.org/10.1179/joc.2005.17.6.593, 2005.
Kuzyk, P. R., Dhotar, H. S., Sternheim, A., Gross, A. E., Safir, O., and
Backstein, D.: Two-stage revision arthroplasty for management of chronic
periprosthetic hip and knee infection: techniques, controversies, and
outcomes, J. Am. Acad. Orthop. Surg., 22, 153–164, https://doi.org/10.5435/JAAOS-22-03-153, 2014.
Levack, A. E., Turajane, K., Yang, X., Miller, A. O., Carli, A. V., Bostrom,
M. P., and Wellman, D. S.: Thermal Stability and in Vitro Elution Kinetics
of Alternative Antibiotics in Polymethylmethacrylate (PMMA) Bone Cement, J.
Bone Joint Surg. Am., 103, 1694–1704, https://doi.org/10.2106/JBJS.20.00011, 2021.
Levack, A. E., Turajane, K., Driscoll, D. A., Yang, X., Miller, A. O.,
Bostrom, M. P., Wellman, D. S., and Carli, A. V.: Identifying alternative
antibiotics that elute from calcium sulfate beads for treatment of
orthopedic infections, J. Orthop. Res., 40, 1143–1153, https://doi.org/10.1002/jor.25135, 2022.
Lichstein, P., Su, S., Hedlund, H., Suh, G., Maloney, W. J., Goodman, S. B.,
and Huddleston 3rd, J. I.: Treatment of Periprosthetic Knee Infection With
a Two-stage Protocol Using Static Spacers, Clin. Orthop. Relat. Res., 474,
120–125, https://doi.org/10.1007/s11999-015-4443-2, 2016.
Malone, M., Goeres, D. M., Gosbell, I., Vickery, K., Jensen, S., and
Stoodley, P.: Approaches to biofilm-associated infections: the need for
standardized and relevant biofilm methods for clinical applications, Expert.
Rev. Anti Infect. Ther., 15, 147–156, https://doi.org/10.1080/14787210.2017.1262257, 2017.
Morgenstern, M., Kuhl, R., Eckardt, H., Acklin, Y., Stanic, B., Garcia, M.,
Baumhoer, D., and Metsemakers, W. J.: Diagnostic challenges and future
perspectives in fracture-related infection, Injury, 49 Suppl 1, S83–S90, https://doi.org/10.1016/S0020-1383(18)30310-3, 2018.
Mortazavi, S. M., Schwartzenberger, J., Austin, M. S., Purtill, J. J., and
Parvizi, J.: Revision total knee arthroplasty infection: incidence and
predictors, Clin. Orthop. Relat. Res., 468, 2052–2059, https://doi.org/10.1007/s11999-010-1308-6, 2010.
Papakostidis, C., Kanakaris, N. K., Pretel, J., Faour, O., Morell, D. J.,
and Giannoudis, P. V.: Prevalence of complications of open tibial shaft
fractures stratified as per the Gustilo-Anderson classification, Injury, 42,
1408–1415, https://doi.org/10.1016/j.injury.2011.10.015, 2011.
Premkumar, A., Kolin, D. A., Farley, K. X., Wilson, J. M., McLawhorn, A. S.,
Cross, M. B., and Sculco, P. K.: Projected Economic Burden of Periprosthetic
Joint Infection of the Hip and Knee in the United States, J. Arthroplasty,
36, 1484–1489, https://doi.org/10.1016/j.arth.2020.12.005, 2021.
Rappo, U., Puttagunta, S., Shevchenko, V., Shevchenko, A., Jandourek, A.,
Gonzalez, P. L., Suen, A., Mas Casullo, V., Melnick, D., Miceli, R.,
Kovacevic, M., De Bock, G., and Dunne, M. W.: Dalbavancin for the Treatment
of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy
and Safety, Open Forum Infect. Dis., 6, ofy331, https://doi.org/10.1093/ofid/ofy331, 2019.
Sader, H. S., Streit, J. M., and Mendes, R. E.: Update on the in vitro
activity of dalbavancin against indicated species (Staphylococcus aureus,
Enterococcus faecalis, beta-hemolytic streptococci, and Streptococcus
anginosus group) collected from United States hospitals in 2017–2019, Diagn.
Microbiol. Infect. Dis., 99, 115195, https://doi.org/10.1016/j.diagmicrobio.2020.115195, 2021.
Saginur, R., Stdenis, M., Ferris, W., Aaron, S. D., Chan, F., Lee, C., and
Ramotar, K.: Multiple combination bactericidal testing of staphylococcal
biofilms from implant-associated infections, Antimicrob. Agents Chemother.,
50, 55–61, https://doi.org/10.1128/AAC.50.1.55-61.2006, 2006.
Simonetti, O., Rizzetto, G., Molinelli, E., Cirioni, O., and Offidani, A.:
Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization,
Ther. Clin. Risk Manag., 17, 223–232, https://doi.org/10.2147/TCRM.S271445, 2021.
Slane, J., Gietman, B., and Squire, M.: Antibiotic elution from acrylic bone
cement loaded with high doses of tobramycin and vancomycin, J. Orthop. Res.,
36, 1078–1085, https://doi.org/10.1002/jor.23722, 2018.
Springer, B. D., Cahue, S., Etkin, C. D., Lewallen, D. G., and McGrory, B.
J.: Infection burden in total hip and knee arthroplasties: an international
registry-based perspective, Arthroplast. Today, 3, 137–140, https://doi.org/10.1016/j.artd.2017.05.003, 2017.
Werth, B. J., Ashford, N. K., Penewit, K., Waalkes, A., Holmes, E. A., Ross,
D. H., Shen, T., Hines, K. M., Salipante, S. J., and Xu, L.: Dalbavancin
exposure in vitro selects for dalbavancin-non-susceptible and
vancomycin-intermediate strains of methicillin-resistant Staphylococcus
aureus, Clin. Microbiol. Infect., 27, e911–910, https://doi.org/10.1016/j.cmi.2020.08.025, 2021.